Brief: Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site
14/05/2025 13:06
May 14 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1/1B STUDY OF PAS-004 IN ADULT NF1 PATIENTS AND ACTIVATION OF FIRST CLINICAL TRIAL SITE Source text: ID:nGNX74DsZR Further company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement